FAS and cancer: The selectivity of TRAIL-R2 is mainly due to the fact that its triggering by TRAIL or TRAIL-agonistic mAbs has an apoptotic effect on cancer cells without the lethal adverse effect on normal cells that has been observed following activation of other death receptors like CD95 (7, 25).